Jubilant Ingrevia Ltd
JUBLINGREA NSE
Jubilant Ingrevia Ltd
ChemicalsNSE: JUBLINGREA BSE: 543271 Specialty Chemicals
Key Fundamentals
MicrocapSpecialty ChemicalsChemicalsMarket Cap
₹11,705 Cr
Volatility
Moderate
P/E Ratio
37.52
EBITDA
₹608 Cr
Return on Equity
8.89%
Debt to Equity
0.25
Book Value
₹201.38
EPS
₹10.93
52W High
₹795
52W Low
₹537.3
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jubilant Ingrevia Ltd insights
48 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has been maintaining a healthy dividend payout of 34.4%
- Company's working capital requirements have reduced from 29.4 days to 22.0 days
Weaknesses
4- Stock is trading at 3.73 times its book value
- Company has a low return on equity of 8.49% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -6.25%
Growth Rate
Revenue Growth
5.06% ↘
Net Income Growth
10.63% ↘
Cash Flow Change
3.18% ↗
ROE
3.61% ↘
ROCE
-2.18% ↘
EBITDA Margin (Avg.)
3.86% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 13d agoAI opinion · based on fundamentals
Risk medium
Jubilant Ingrevia Ltd is a mid-cap specialty chemicals company with a market cap of ₹12,161 crore trading at a PE of 39.1x. FY26 consolidated revenue was ₹4,388 crore (up 5% YoY) with PAT of ₹278 crore (up 11% YoY), while the 3-year compounded sales and profit growth remain negative at -3% and -2% respectively, indicating a recent recovery from a subdued period.
Bull Case 8
- Q4 FY26 revenue grew 12% YoY and EBITDA grew 11% YoY, marking the highest quarterly revenue and EBITDA in 14 quarters
- Q4 FY26 PAT surged 153% YoY to approximately ₹74 crore, showing sharp profit recovery
- FY26 full-year PAT grew 11% YoY to ₹278 crore, demonstrating consistent earnings improvement
- EBITDA margin improved to 14.7% in Q4 FY25 from lower levels in prior quarters, with FY26 EBITDA at ₹607 crore (up 9% YoY)
- Working capital days reduced from 29.4 days to 22.0 days, freeing up cash for operations and capex
- Healthy dividend payout of 29.6% with total dividend of ₹5/share for FY25, signaling confidence in cash generation
- TTM sales growth of 11% and TTM profit growth of 15% indicate an inflection from the negative 3-year CAGR period
- 5-year compounded sales CAGR of 45% and profit CAGR of 35% reflect structural long-term revenue scale-up since demerger
Bear Case 8
- 3-year compounded sales CAGR is -3% and profit CAGR is -2%, indicating a prolonged growth slump between FY22-FY25
- PE of 39.1x is elevated for a chemicals company with only 8.48% 3-year average ROE, suggesting stretched valuations
- Promoter holding has declined by 6.25% over the last 3 years, raising questions about insider confidence
- Stock trades at 3.86x book value despite sub-10% ROE, offering limited margin of safety
- Company may be capitalizing interest costs, which could overstate reported profits and asset values
- 1-year stock CAGR of only 1% despite broader market gains suggests market skepticism about near-term earnings power
- Q4 FY25 revenue of ₹1,051 crore was actually down 2% QoQ from ₹1,074 crore in Q4 FY24, showing uneven recovery
- Dividend yield of only 0.66% provides minimal income cushion at current valuation levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 14d ago Positives 2
- Q1 profit surges 41% YoY Jul 27
Net profit rose 41% to ₹106 crore on revenue of ₹1,300 crore (up 25% YoY). EBITDA reached ₹209 crore at 16% margin with full-year guidance of ₹750-800 crore maintained.
- ₹2.50 final dividend declared Aug 1
Board recommended ₹2.50 per share final dividend for FY 2025-26, to be approved at AGM on August 26, 2026. Directors Shyam S. Bhartia and Priyavrat Bhartia proposed for re-appointment.
Neutral 3
- 7th AGM scheduled Aug 26 Aug 2
Jubilant Ingrevia will hold its 7th AGM via video conference on August 26, 2026, with voting on dividend and director re-appointments.
- FY26 BRSR report filed Aug 1
Company submitted its Business Responsibility and Sustainability Report for FY26 detailing ESG performance, safety metrics, and environmental targets.
- Q1FY27 earnings call hosted Jul 13
Investor conference call was held on July 23, 2026 to discuss unaudited financial results for the quarter ended June 30, 2026.
TL;DR: Jubilant Ingrevia is delivering strong execution with 41% profit growth and 25% revenue growth in Q1FY27, driven by Fine Chemicals, CDMO, and Nutrition segments. No visible headwinds in recent news flow. The company maintained its ₹750-800 crore EBITDA guidance, signalling management confidence. The trend is clearly improving with broad-based segment strength and shareholder returns via dividends.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,075 | 1,020 | 966 | 1,074 | 1,024 | 1,045 | 1,057 | 1,051 | 1,038 | 1,121 | 1,051 | 1,179 | 1,300 |
| Expenses | 958 | 902 | 871 | 983 | 915 | 921 | 918 | 905 | 896 | 985 | 924 | 1,016 | 1,101 |
| Operating Profit | 117 | 118 | 96 | 91 | 110 | 124 | 138 | 147 | 142 | 135 | 126 | 163 | 199 |
| OPM % | 11% | 12% | 10% | 8% | 11% | 12% | 13% | 14% | 14% | 12% | 12% | 14% | 15% |
| Other Income | 8 | 9 | 9 | 10 | 10 | 10 | 9 | 8 | 11 | 11 | -4 | 9 | 10 |
| Interest | 11 | 13 | 15 | 14 | 14 | 15 | 12 | 14 | 13 | 12 | 12 | 12 | 17 |
| Depreciation | 32 | 34 | 34 | 36 | 39 | 40 | 40 | 39 | 41 | 41 | 45 | 48 | 51 |
| PBT | 81 | 80 | 55 | 51 | 66 | 80 | 96 | 102 | 100 | 93 | 65 | 112 | 141 |
| Tax % | 29% | 28% | 30% | 43% | 26% | 26% | 27% | 27% | 25% | 25% | 28% | 23% | 25% |
| Net Profit | 58 | 57 | 39 | 29 | 49 | 59 | 69 | 74 | 75 | 69 | 47 | 86 | 106 |
| EPS in Rs | 3.62 | 3.61 | 2.42 | 1.84 | 3.06 | 3.7 | 4.36 | 4.65 | 4.71 | 4.36 | 2.94 | 5.43 | 6.64 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 684 | 4,949 | 4,773 | 4,136 | 4,178 | 4,388 | 4,651 |
| Expenses | 0 | 567 | 4,108 | 4,224 | 3,708 | 3,658 | 3,820 | 4,027 |
| Operating Profit | 0 | 117 | 841 | 549 | 427 | 519 | 568 | 624 |
| OPM % | — | 17% | 17% | 11% | 10% | 12% | 13% | 13% |
| Other Income | 0 | -10 | 22 | 32 | 29 | 38 | 27 | 27 |
| Interest | 0 | 7 | 31 | 22 | 53 | 56 | 49 | 54 |
| Depreciation | 0 | 22 | 123 | 122 | 136 | 158 | 175 | 186 |
| PBT | 0 | 77 | 709 | 437 | 268 | 344 | 370 | 411 |
| Tax % | 0% | 30% | 33% | 30% | 32% | 27% | 25% | — |
| Net Profit | 0 | 54 | 477 | 308 | 183 | 251 | 278 | 309 |
| EPS in Rs | -3.4 | 3.41 | 29.93 | 19.31 | 11.48 | 15.77 | 17.45 | 19.37 |
| Div. Payout % | 0% | 10% | 17% | 26% | 43% | 31% | 28% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 0 | 1,907 | 2,417 | 2,650 | 2,722 | 2,911 | 3,110 |
| Borrowings | 0 | 556 | 238 | 407 | 740 | 764 | 792 |
| Other Liabilities | 0 | 888 | 1,111 | 1,176 | 1,241 | 1,324 | 1,551 |
| Total Liabilities | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,015 | 5,470 |
| Fixed Assets | 0 | 1,805 | 1,798 | 1,846 | 2,539 | 2,581 | 3,183 |
| CWIP | 0 | 65 | 174 | 525 | 331 | 525 | 154 |
| Investments | 0 | 50 | 6 | 8 | 15 | 37 | 33 |
| Other Assets | 0 | 1,446 | 1,804 | 1,870 | 1,834 | 1,872 | 2,099 |
| Total Assets | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,015 | 5,470 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 0 | 112 | 453 | 462 | 430 | 508 | 524 |
| Investing | 0 | 33 | -71 | -469 | -568 | -389 | -250 |
| Financing | 0 | -72 | -418 | 42 | 144 | -129 | -155 |
| Net Cash Flow | 0 | 73 | -36 | 35 | 6 | -9 | 119 |
| Free Cash Flow | 0 | 85 | 225 | -16 | -136 | 156 | 235 |
| CFO/OP | 0 | 106 | 69 | 98 | 111 | 113 | 111 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | — | 251 | 43 | 39 | 50 | 53 | 65 |
| Inventory Days | — | 601 | 117 | 146 | 160 | 163 | 140 |
| Days Payable | — | 685 | 103 | 113 | 131 | 141 | 150 |
| Cash Conversion Cycle | — | 167 | 57 | 72 | 80 | 75 | 55 |
| Working Capital Days | — | 220 | 49 | 42 | 37 | 29 | 22 |
| ROCE % | — | 8% | 29% | 16% | 10% | 11% | 11% |
Documents
1
Board Meeting Intimation for Intimation Of Board Meeting - May 26, 2026
28 Apr - Board meets May 26, 2026 to approve audited FY26 results and consider final dividend. 28 Apr - Board meets May 26, 2026 to approve audited FY26 results and consider final dividend.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
28 Apr - Schedule for Investor Conference Call for Jubilant Ingrevia Limited -Audited Financial Results for the quarter and year ended March 31, 2026 28 Apr - Schedule for Investor Conference Call for Jubilant Ingrevia Limited -Audited Financial Results for the quarter and year ended March 31, 2026
3
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
5 May - Appeal order confirms FY17-18 GST demand of Rs 1.02 crore, equal penalty and interest; company will appeal GSTAT. 5 May - Appeal order confirms FY17-18 GST demand of Rs 1.02 crore, equal penalty and interest; company will appeal GSTAT.
4
Clarification On Price Movement In Shares Of Jubilant Ingrevia Limited
23 Apr - Jubilant Ingrevia clarified on April 23, 2026 that no material unpublished information exists. 23 Apr - Jubilant Ingrevia clarified on April 23, 2026 that no material unpublished information exists.
5
Grant Of Stock Options Under Jubilant Ingrevia Employees Stock Option Plan 2021
21 Apr - Jubilant Ingrevia granted 3,43,569 stock options under ESOP 2021, vesting after FY30. 21 Apr - Jubilant Ingrevia granted 3,43,569 stock options under ESOP 2021, vesting after FY30.
Frequently Asked Questions about Jubilant Ingrevia Ltd
What does Jubilant Ingrevia Ltd do?
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality sta...
Where is Jubilant Ingrevia Ltd (JUBLINGREA) listed?
Jubilant Ingrevia Ltd is listed on the Indian stock exchanges. It is listed on NSE: JUBLINGREA and BSE: 543271. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jubilant Ingrevia Ltd belong to?
Jubilant Ingrevia Ltd operates in the Chemicals sector within the Specialty Chemicals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd has a market capitalisation of approximately ₹11704.77 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jubilant Ingrevia Ltd?
The Price-to-Earnings (PE) ratio of Jubilant Ingrevia Ltd is 37.52. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jubilant Ingrevia Ltd?
Over the past 52 weeks, Jubilant Ingrevia Ltd has traded between a low of ₹537.3 and a high of ₹795. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jubilant Ingrevia Ltd pay dividends?
Yes, Jubilant Ingrevia Ltd has a dividend yield of 0.68%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd has a Return on Equity (ROE) of 8.89%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jubilant Ingrevia Ltd on Tapetide?
On Tapetide, you can view Jubilant Ingrevia Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]